|1.||Nicolau, David P: 11 articles (01/2015 - 08/2004)|
|2.||Bonomo, Robert A: 9 articles (08/2015 - 10/2005)|
|3.||Paterson, David L: 8 articles (08/2015 - 10/2005)|
|4.||Rodríguez-Baño, Jesús: 7 articles (09/2015 - 10/2008)|
|5.||Vakulenko, Sergei B: 7 articles (01/2015 - 10/2009)|
|6.||Hsueh, Po-Ren: 7 articles (11/2014 - 01/2005)|
|7.||Nordmann, Patrice: 6 articles (10/2015 - 02/2009)|
|8.||Kaye, Keith S: 6 articles (08/2015 - 04/2012)|
|9.||Pitout, Johann D D: 5 articles (10/2015 - 03/2008)|
|10.||Frase, Hilary: 5 articles (01/2015 - 10/2009)|
08/01/2011 - "Although CPKP isolates are often highly resistant to carbapenems, a proportion of these have relatively low MICs for carbapenems, raising the question of whether this class of agents has any therapeutic potential against CPKP infections. "
01/01/1999 - "Full efficacy of carbapenems and high usefulness of ciprofloxacine in the treatment of infections were confirmed. "
06/01/2015 - "An increase in the use of carbapenems in first-line treatment is a major environmental hazard and exposes the patient to the risk of untreatable infections. "
10/01/2014 - "Carbapenems are a mainstay of treatment for infections caused by Pseudomonas aeruginosa. "
03/01/2011 - "In the rabbit experimental model, carbapenems were shown to be effective in the treatment of intra-abdominal infection due to an extended-spectrum β-lactamase-negative carbapenem-susceptible VIM-1-producing clinical E. "
|2.||Cross Infection (Nosocomial Infection)
06/01/2010 - "Baumannii, in the two study hospitals and suggest that clinicians can still administer carbapenems as a reliable and effective choice in managing serious nosocomial infections."
05/01/2015 - "The development of resistance to carbapenems have become an increasing problem in the treatment of nosocomial infections. "
02/01/2014 - "Carbapenems are first-line agents for the treatment of serious nosocomial infections caused by multidrug-resistant Enterobacteriaceae. "
05/01/2012 - "Carbapenems are the major weapons in the treatment of nosocomial infections. "
01/01/2011 - "Although carbapenem antibiotics are one of the most effective agents in the treatment of nosocomial infections caused by Gram-negative bacteria, their use is threatened by the emergence of antibiotic resistance. "
10/01/2007 - "The clinical features of most cases were: (1) pneumonia in the elderly with cerebrovascular diseases, (2) previous administration of carbapenems and antipseudomonal cephems, (3) PIPC, CAZ and ISP sensitve MDRP, (4) MRSA was isolated concurrently, (5) not necessary of therapy against MDRP, (6) good outcome."
12/01/2011 - "Clinical efficacy of carbapenems on hospital-acquired pneumonia in accordance with the Japanese Respiratory Society Guidelines for management of HAP."
09/01/1997 - "In the case of nosocomial pneumonias, all the studies have evaluated the carbapenems in monotherapy as useful and effective, specially in the case of pneumonia by gram negative bacilli. "
08/01/2015 - "Carbapenems were rarely used during the intervention period in cases of pneumonia (CAP: 12% vs. 1%, HCAP: 13% vs. 1%), while antipseudomonal beta-lactam use was reduced from 33% to 8% among cases with HCAP. "
08/01/2015 - "Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia."
10/01/2014 - "We aimed to evaluate the efficacy of non-carbapenem antibiotics for acute pyelonephritis (APN) due to ESBL-producing E. "
10/01/2014 - "The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli."
03/01/2013 - "We therefore evaluated the efficacy of cefmetazole compared to carbapenems against pyelonephritis caused by ESBL-producing Enterobacteriaceae. "
12/01/2009 - "Efficacy of treatment with carbapenems and third-generation cephalosporins for patients with febrile complicated pyelonephritis."
08/01/2001 - "For pyelonephritis, switch therapy using aminoglycosides and fluoroquinolones, carbapenems, third-generation cephalosporines, or penicillins are selections of choice. "
06/01/2014 - "This study aimed to examine the rates of presumed hypersensitivity reactions in a large cohort of patients receiving carbapenem antibiotics. "
04/01/2010 - "Drug-induced hypersensitivity syndrome due to carbapenem antibiotics."
01/01/2009 - "Caution should be used in patients with hypersensitivity to carbapenems and adverse reactions to β-lactam agents. "
04/01/1989 - "Therefore, it appears that the ability of certain carbapenem antibiotics to produce a high incidence of type II hypersensitivity reactions in animals is not typical of beta-lactam compounds in general."
12/01/2004 - "Based on this study and other similar studies, the true incidence of cross-hypersensitivity reactions between penicillin and carbapenems may be lower than previously reported. "
|1.||Cephalosporins (Cephalosporin Antibiotics)
|4.||imipenem drug combination cilastatin (Primaxin)
|5.||Anti-Bacterial Agents (Antibiotics)
|1.||Intensive Care (Surgical Intensive Care)
|2.||Artificial Respiration (Mechanical Ventilation)
|4.||Length of Stay
|5.||Drug Therapy (Chemotherapy)